Page 37«..1020..36373839..5060..»

Lupus arises from complex interplay of genetic and environmental factors – Environmental Factor Newsletter

Posted: July 2, 2024 at 2:37 am

Criswell also heads the Genomics of Autoimmune Rheumatic Disease Section of the National Human Genome Research Institute. (Photo courtesy of Steve McCaw / NIEHS)

Few subjects in medical research are more vexing than lupus, a multifaceted chronic autoimmune disease that has no diagnostic test or cure. Yet in a June 11 Distinguished Lecture, Lindsey A. Criswell, M.D., M.P.H., D.Sc., director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and head of the Genomics of Autoimmune Rheumatic Disease Section at the National Human Genome Research Institute (NHGRI), highlighted promising steps forward in understanding the genetic and environmental causes of lupus.

Lisa Rider, M.D., head of the NIEHS Environmental Autoimmunity Group, hosted the lecture. During her NIEHS visit, Criswell and NIEHS Director Rick Woychik, Ph.D., also discussed opportunities to bolster collaborations across their respective institutes in areas of shared interest. Environmental contributions to autoimmune disease and the application of exposomics to studies of autoimmune disease and other chronic conditions are among topics of mutual interest.

Compared to other autoimmune diseases, lupus, overall, has a relatively strong genetic contribution, Criswell said.

For example, risk factors for lupus and other autoimmune diseases have been identified on chromosome 6, particularly within the major histocompatibility complex, which contains genes important to the immune response.

Although a large number of genetic variants have been associated with lupus, Criswell said, more work is needed to understand the basic biological mechanisms underlying the disease.

The criteria for diagnosing lupus are not driven by biology or disease understanding, she said. They're based on clinical and laboratory features.

Still, these disease features have been useful. For example, patients with lupus who produce antibodies to double-stranded DNA are more likely to have severe disease, such as kidney involvement.

Also, smokers are more likely to have severe rheumatoid arthritis characterized by anti-CCP [cyclic citrullinated peptide] autoantibodies, said Criswell.

Epigenetic factors, which affect gene function but do not change the underlying genetic code, play a significant role in the development of autoimmune diseases. One way scientists have explored epigenetics is through the study of identical twins, who begin life with the same genetic blueprint, altered differentially over time by environmental exposures.

Research on identical twin pairs where one twin has lupus and the other does not have revealed an association between disease status and DNA methylation, which is the addition of methyl tags to DNA that influences the level of expression of genes.

While DNA methylation controls gene expression to a great extent, methylation itself may be mediating some of the genetic contribution to the disease, Criswell said.

DNA methylation can be influenced by a variety of environmental factors, such as exposure to metals, pesticides, or oxidative stress brought on by smoke or air pollution (see sidebar). In some cases, specific DNA methylation changes have been linked with specific environmental exposures, suggesting that DNA methylation may serve as a useful biomarker.

Compared to genetic factors, Criswell said, the potential number of environmental influences on the disease is vast. Still, the quality of the environmental risk factor evidence is limited, and in some cases anecdotal.

Its been difficult to study the environmental contributions in a rigorous, comprehensive, and systematic way, she said.

During the Q&A, several NIEHS leaders wanted to know more about how gene-environment interactions could explain the development of lupus and point to potential treatments for the disease. Woychik asked to what extent do genetics and epigenetics crosstalk, or interact, in the suppression of gene activity.

What I can say is that genetic variants don't fully explain disease risk, Criswell said. DNA methylation controls gene expression to a great extent, and some genetic variants influence disease risk through differences in methylation. Is the methylation under genetic control, or is it mediating genetic association with disease? DNA methylation is telling us something above and beyond what we can glean from the underlying genetics.

NIEHS Scientific Director Darryl Zeldin, M.D., wondered about how lupus treatment may change over the next 10 years. He asked: Will we be able to take a personalized medicine approach and decide which treatments are best in a particular patient?

One reason most clinical trials on lupus have failed is we don't fully understand the underlying biology, Criswell said. But new therapies will eventually be suggested by ongoing research in this area. We have tools to get there. Drug repurposing, for example, holds tremendous promise.

Fred Miller, M.D., Ph.D., scientist emeritus at the NIEHS Environmental Autoimmunity Group (now headed by Rider), asked: In what ways are you putting environmental exposures together into a gene-environment interaction approach?

To that end, Criswell is collaborating with the NIEHS Metabolomics Core facility to compare levels of chemicals in samples collected from patients during periods of high versus low lupus activity. Genetic and epigenetic data is also available for these individuals, allowing her team to study the combination of these factors on disease risk and severity. In addition, Criswell recently received support through the Intramural Targeted Climate Change & Health program to study the effects of wildfire smoke exposure on the epigenome and health in a multiethnic cohort.

Since I was a kid, I've been fascinated by nature versus nurture, genes and environment, Criswell said. The environmental piece has been much more complicated, but I can imagine a future where we understand the major environmental contributions to lupus.

(John Yewell is a contract writer for the NIEHS Office of Communications and Public Liaison.)

See the original post here:
Lupus arises from complex interplay of genetic and environmental factors - Environmental Factor Newsletter

Posted in Epigenetics | Comments Off on Lupus arises from complex interplay of genetic and environmental factors – Environmental Factor Newsletter

Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future … – Nature.com

Posted: July 2, 2024 at 2:37 am

Cao, H., Duan, L., Zhang, Y., Cao, J. & Zhang, K. Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. Signal Transduct. Tar. 6, 426 (2021).

Article CAS Google Scholar

Zhang, Z. Z. et al. Improving the ability of CAR-T cells to hit solid tumors: challenges and strategies. Pharm. Res. 175, 106036 (2022).

Article CAS Google Scholar

Yan, Z. et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front. Immunol. 12, 611366 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zhang, Y. et al. Reactive oxygen species-responsive and Raman-traceable hydrogel combining photodynamic and immune therapy for postsurgical cancer treatment. Nat. Commun. 13, 4553 (2022).

Article CAS PubMed PubMed Central Google Scholar

DuVall, G. A., Tarabar, D., Seidel, R. H., Elstad, N. L. & Fowers, K. D. Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anti-Cancer Drugs 20, 8995 (2009).

Article CAS PubMed Google Scholar

Nuhn, L. et al. Cationic nanohydrogel particles as potential siRNA carriers for cellular delivery. ACS Nano 6, 21982214 (2012).

Article CAS PubMed Google Scholar

Liu, Y. et al. Enhancing stem cell therapy for cartilage repair in osteoarthritis-a hydrogel focused approach. Gels 7, 263 (2021).

Article PubMed PubMed Central Google Scholar

Norouzi, M., Nazari, B. & Miller, D. W. Injectable hydrogel-based drug delivery systems for local cancer therapy. Drug Discov. Today 21, 18351849 (2016).

Article CAS PubMed Google Scholar

Liu, G., Zhou, Y., Zhang, X. & Guo, S. Advances in hydrogels for stem cell therapy: regulation mechanisms and tissue engineering applications. J. Mater. Chem. B 10, 55205536 (2022).

Article CAS PubMed Google Scholar

Oura, K., Morishita, A., Tani, J. & Masaki, T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int. J. Mol. Sci. 22, 5801 (2021).

Article CAS PubMed PubMed Central Google Scholar

Ran, G. H. et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct. Tar. 7, 205 (2022).

Article CAS Google Scholar

Gao, W., Zhang, Y., Zhang, Q. & Zhang, L. Nanoparticle-hydrogel: a hybrid biomaterial system for localized drug delivery. Annu. Biomed. Eng. 44, 20492061 (2016).

Article Google Scholar

Ledford, B., Barron, C., Van Dyke, M. & He, J. Q. Keratose hydrogel for tissue regeneration and drug delivery. Semin. Cell Dev. Biol. 128, 145153 (2022).

Article CAS PubMed Google Scholar

Mo, F. et al. DNA hydrogel-based gene editing and drug delivery systems. Adv. Drug Deliv. Rev. 168, 7998 (2021).

Article CAS PubMed Google Scholar

Wang, Y., Malcolm, D. W. & Benoit, D. S. W. Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing. Biomaterials 139, 127138 (2017).

Article CAS PubMed PubMed Central Google Scholar

Zhang, R. et al. Polyvinyl alcohol/gelatin hydrogels regulate cell adhesion and chromatin accessibility. Int. J. Biol. Macromol. 219, 672684 (2022).

Article CAS PubMed Google Scholar

Zhou, J., Du, X. & Xu, B. Regulating the rate of molecular self-assembly for targeting cancer cells. Angew. Chem. Int. Ed. Engl. 55, 57705775 (2016).

Article CAS PubMed PubMed Central Google Scholar

Shi, W., Ji, Y., Zhang, X., Shu, S. & Wu, Z. Characterization of ph- and thermosensitive hydrogel as a vehicle for controlled protein delivery. J. Pharm. Sci.- 100, 886895 (2011).

Article CAS PubMed Google Scholar

Dhawan, S., Kapil, R. & Kapoor, D. N. Development and evaluation of in situ gel-forming system for sustained delivery of insulin. J. Biomater. Appl. 25, 699720 (2011).

Article CAS PubMed Google Scholar

Fennell, E. & Huyghe, J. M. Chemically responsive hydrogel deformation mechanics: a review. Molecules 24, 3521 (2019).

Article CAS PubMed PubMed Central Google Scholar

Zhang, D. et al. From design to applications of stimuli-responsive hydrogel strain sensors. J. Mater. Chem. B 8, 31713191 (2020).

Article CAS PubMed Google Scholar

Zhou, J. et al. pH-responsive nanocomposite hydrogel for simultaneous prevention of postoperative adhesion and tumor recurrence. Acta Biomater. 158, 228238 (2023).

Article CAS PubMed Google Scholar

Zhang, J. T., Huang, S. W. & Zhuo, R. X. Temperature-sensitive polyamidoamine dendrimer/poly(N-isopropylacrylamide) hydrogels with improved responsive properties. Macromol. Biosci. 4, 575578 (2004).

Article CAS PubMed Google Scholar

Chen, S. X. et al. In situ forming oxygen/ROS-responsive niche-like hydrogel enabling gelation-triggered chemotherapy and inhibition of metastasis. Bioact. Mater. 21, 8696 (2023).

CAS PubMed Google Scholar

Rajesh Krishnan, G., Cheah, C. & Sarkar, D. Hybrid cross-linking characteristics of hydrogel control stem cell fate. Macromol. Biosci. 15, 747755 (2015).

Article CAS PubMed Google Scholar

Stanzione, A. et al. Thermosensitive chitosan-based hydrogels supporting motor neuron-like NSC-34 cell differentiation. Biomater. Sci. 9, 74927503 (2021).

Article CAS PubMed Google Scholar

Tsao, C. T. et al. Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy. Biomacromolecules 15, 26562662 (2014).

Article CAS PubMed PubMed Central Google Scholar

Hu, Q. et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat. Biomed. Eng. 5, 10381047 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zheng, Y. et al. Neuro-regenerative imidazole-functionalized GelMA hydrogel loaded with hAMSC and SDF-1 promote stem cell differentiation and repair focal brain injury. Bioact. Mater. 6, 627637 (2021).

CAS PubMed Google Scholar

Xu, T. et al. Composite hemostat spray seals post-surgical blood burst and ameliorates bacteria-arised inflammation for expediting wound healing. ACS Mater. Lett. 5, 18921901 (2023).

Article CAS Google Scholar

Ning, S. et al. Injectable thermo-sensitive hydrogel loaded hollow copper sulfide nanoparticles for ROS burst in TME and effective tumor treatment. Front. Bioeng. Biotech. 11, 1191014 (2023).

Article Google Scholar

Zeng, W. et al. An injectable hydrogel for enhanced FeGA-based chemodynamic therapy by increasing intracellular acidity. Front. Oncol. 11, 750855 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zimmermann, U. et al. Hydrogel-based non-autologous cell and tissue therapy. Biotechniques 29, 564572 (2000). 574, 576 passim.

Article CAS PubMed Google Scholar

Li, Q. et al. PEG-interpenetrated genipin-crosslinked dual-sensitive hydrogel/nanostructured lipid carrier compound formulation for topical drug administration. Artif. Cells Nanomed. B 49, 345353 (2021).

Article Google Scholar

Gholamali, I. & Yadollahi, M. Doxorubicin-loaded carboxymethyl cellulose/Starch/ZnO nanocomposite hydrogel beads as an anticancer drug carrier agent. Int. J. Biol. Macromol. 160, 724735 (2020).

Article CAS PubMed Google Scholar

Snigdha, K., Singh, B. K., Mehta, A. S., Tewari, R. P. & Dutta, P. K. Self-assembling N-(9-fluorenylmethoxycarbonyl)-l-phenylalanine hydrogel as novel drug carrier. Int. J. Biol. Macromol. 93, 16391646 (2016).

Article CAS PubMed Google Scholar

Jin, H. et al. Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel. ACS Nano 12, 32953310 (2018).

Article CAS PubMed Google Scholar

Seo, H. W. et al. Injectable intratumoral hydrogel as 5-fluorouracil drug depot. Biomaterials 34, 27482757 (2013).

Article CAS PubMed Google Scholar

Wang, D. et al. Extracellular matrix viscosity reprogramming by in situ Au bioreactor-boosted microwavegenetics disables tumor escape in CAR-T immunotherapy. ACS Nano 17, 55035516 (2023).

Article CAS PubMed Google Scholar

Song, W. et al. Recent studies on hydrogels based on H(2)O(2)-responsive moieties: mechanism, preparation and application. Gels 8, 361 (2022).

Article CAS PubMed PubMed Central Google Scholar

Lu, L. et al. Oncolytic impediment/promotion balance disruption by sonosensitizer-free nanoplatforms unfreezes autophagy-induced resistance to sonocatalytic therapy. ACS Appl. Mater. Int. 14, 3646236472 (2022).

Article CAS Google Scholar

Rapp, T. L. & DeForest, C. A. Visible light-responsive dynamic biomaterials: going deeper and triggering more. Adv. Health. Mater. 9, e1901553 (2020).

Article Google Scholar

Murdan, S. Electro-responsive drug delivery from hydrogels. J. Control Release 92, 117 (2003).

Article CAS PubMed Google Scholar

Arajo-Custdio, S. et al. Injectable and magnetic responsive hydrogels with bioinspired ordered structures. ACS Biomater. Sci. Eng. 5, 13921404 (2019).

Article PubMed Google Scholar

Janga, K. Y. et al. Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: in vitro permeability, cytotoxicity and in vivo evaluation. Artif. Cells Nanomed. B 46, 10391050 (2018).

Article CAS Google Scholar

Unger, K. & Coclite, A. M. Glucose-responsive boronic acid hydrogel thin films obtained via initiated chemical vapor deposition. Biomacromolecules 23, 42894295 (2022).

Article CAS PubMed PubMed Central Google Scholar

Field, R. D. et al. Ultrasound-responsive aqueous two-phase microcapsules for on-demand drug release. Angew. Chem. Int. Ed. Engl. 61, e202116515 (2022).

Article CAS PubMed Google Scholar

Fischbach, M. A., Bluestone, J. A. & Lim, W. A. Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med. 5, 179ps7 (2013).

Article PubMed PubMed Central Google Scholar

Wang, L. L. et al. Cell therapies in the clinic. Bioeng. Transl. Med. 6, e10214 (2021).

Article PubMed PubMed Central Google Scholar

Irvine, D. J., Maus, M. V., Mooney, D. J. & Wong, W. W. The future of engineered immune cell therapies. Science 378, 853858 (2022).

Article CAS PubMed PubMed Central Google Scholar

Here is the original post:
Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future ... - Nature.com

Posted in Stem Cell Therapy | Comments Off on Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future … – Nature.com

Stem cell therapies show promise as epidermolysis bullosa treatment – Epidermolysis Bullosa News

Posted: July 2, 2024 at 2:37 am

Both bone marrow transplant and treatment with stem cells derived from bone marrow may help ease symptoms in some people with epidermolysis bullosa (EB), although a bone marrow transplant carries substantial greater safety risks.

Thats according to the review study Bone marrow transplantation and bone marrow-derived mesenchymal stem cell therapy in epidermolysis bullosa: A systematic review, which was published in Pediatric Dermatology.

EB is a group of rare diseases marked by fragile skin that easily blisters. It is caused by mutations that most commonly affect the formation of skin layers.

Supportive care has been the mainstay of therapy for all forms of EB to prevent or respond to disease progression, the researchers wrote.

But bone marrow transplants and stem cell therapies have been explored in EB treatment, with the idea being that providing healthy stem cells may promote healthy skin layers to develop.

Stem cells are specialized cells that can grow into other types of cells and help coordinate biological activities like inflammation and tissue repair.

Different types of stem cells can be found in bone marrow, including hematopoietic stem cells, which are responsible for making new blood cells, and mesenchymal stem cells, which can grow into several types of cells, including those that make up the skin.

Specific stem cell procedures used in EB are bone marrow transplant (BMT) and bone marrow-derived mesenchymal stem cell (BM-MSC) therapy. BMT is a highly invasive process that involves collecting healthy bone marrow stem cells and administering them into a patients bloodstream after treatment with chemotherapy and/or radiation to wipe out existing bone marrow stem cells. BM-MSC therapy is a less invasive procedure where mesenchymal stem cells are infused into a patients bloodstream or administered directly into the skin.

Here, scientists in Indonesia systematically reviewed published studies up to June 2023 that report the outcomes of BMT and BM-MSC therapy in people with EB. Twelve studies that covered 55 patients were included in the final analyses. Almost all the patients had dystrophic EB, while two had junctional EB. Most (63.6%) had BM-MSC therapy, but eight (14.5%) had BMT. Twelve patients (21.8%) had both procedures.

Patients tended to see reductions in disease symptoms after BMT and/or BM-MSC, results showed. However, the rates of recovery and ultimate outcomes varied from person to person, with some seeing better outcomes than others for reasons that arent fully clear.

Although efficacy results were generally positive, the researchers noted that BMT was associated with side effects. BMT, alone or combined with BM-MSC therapy, resulted in graft failure, meaning the transplanted cells were unable to take root, in five patients. There also were five cases of graft-versus-host disease, an immune complication wherein the transplanted cells attack the patients own cells, and five cases of sepsis, a severe blood infection, with BMT.

Pre-BMT chemotherapy or radiotherapy to kill existing bone marrow stem cells weakens the bodys immune system and increases the risk of infections. Among those who had BMT, two patients died of sepsis and another died of cardiac arrest due to pulmonary infections in the setting of chronic lung disease.

Compared with BMT, BM-MSC therapy was much more well tolerated, with no serious side effects reported. No deaths were reported in the BM-MSC therapy group. Two patients developed a temporary abnormal odor linked to the procedure and two developed squamous cell carcinoma, a common type of skin cancer. Its unclear if the treatment caused or expedited the cancer to develop.

Despite its potential advantages for severe forms of EB, bone marrow transplantation is a high-risk therapeutic modality with various adverse events; however, BM-MSCs showed promising results and improved safety of EB cell-based therapy treatment, wrote the researchers, who noted their review was limited by the small number of studies and that there was little data on the treatments affect on patients quality of life. Further study is needed regarding cost, access, and long-term risks of these therapies.

View original post here:
Stem cell therapies show promise as epidermolysis bullosa treatment - Epidermolysis Bullosa News

Posted in Stem Cell Therapy | Comments Off on Stem cell therapies show promise as epidermolysis bullosa treatment – Epidermolysis Bullosa News

Sheffield Univ. Advances in Rare Bowel Disease Stem Cell Therapy – Mirage News

Posted: July 2, 2024 at 2:37 am

Stem cell therapy could be used to treat sufferers of a rare bowel disease, a new study led by researchers at the University of Sheffield and University College London (UCL), has demonstrated.

Hirschsprung disease is a rare condition where some nerve cells are missing in the large intestine. This means the intestine cannot contract or move stool and therefore can become blocked. This can cause constipation and sometimes lead to a serious bowel infection called enterocolitis.

Around 1 in 5,000 babies are born with Hirschsprung disease. The condition is usually picked up soon after birth and treated with surgery as soon as possible; however patients frequently suffer debilitating, lifelong symptoms, with multiple surgical procedures often required.

For the first time, researchers have now used stem cell therapy in human tissue from people with Hirschsprung disease to generate nerve cell precursors, which then produce the missing nerves in the intestine after transplantation. This in turn should improve the intestine's functionality. It is hoped the discovery could lead to improved symptoms and better outcomes for individuals with the disease.

Dr Anestis Tsakiridis, Principal Investigator at University of Sheffield said: "Our findings have laid the foundations for the future development of a cell therapy against Hirschsprung disease and we will continue our efforts to bring this to the clinic in the next few years.

"This has been a fantastic collaboration, led by two talented early career scientists, Dr Ben Jevans and Fay Cooper."

The research, published in Gut and funded by the Medical Research Council, is a collaborative effort between researchers at the University of Sheffield and UCL which began in 2017.

Researchers at the University of Sheffield focused on the production and analysis of nerve precursors from stem cells. These were then shipped to the UCL team, who prepared the patient gut tissue, undertook the transplantation and maintenance of the tissue and then tested the function of the tissue segments.

The study involved taking tissue samples donated by GOSH patients with Hirschsprung disease as a part of their routine treatment, which were then cultured in the lab. The samples were transplanted with stem cell-derived nerve cell precursors which then developed into the crucial nerve cells within the gut tissue.

Importantly, the transplanted gut samples showed increased ability to contract compared to control tissue, suggesting improved functionality of the gut in those with the disease.

Principal Investigator, Dr Conor McCann from UCL Great Ormond Street Institute of Child Health, added: "This study is a real breakthrough in our cell therapy work for Hirschsprung disease. It really shows the benefit of bringing the expertise of different groups together which will hopefully benefit children and adults living with Hirschsprung disease in the future."

Researchers will now be applying for further funding for clinical trials to develop this treatment.

Original post:
Sheffield Univ. Advances in Rare Bowel Disease Stem Cell Therapy - Mirage News

Posted in Stem Cell Therapy | Comments Off on Sheffield Univ. Advances in Rare Bowel Disease Stem Cell Therapy – Mirage News

Advancing regenerative medicine therapies UCI News – UCI News

Posted: July 2, 2024 at 2:35 am

University and community guests recently gathered to celebrate the 7,700 square-foot Good Manufacturing Practice facilitys grand opening in Hewitt Halls basement on the UC Irvine campus. Although the highly sterile environment remains off-limits for tours, the gala highlighted its importance to the campus, the UC system and the local community.

This facility is not just a building; it is a powerhouse of innovation and hope, meticulously designed and equipped to produce FDA-compliant cell and gene therapies, which are at the forefront of medical sciences promise for the future, says Dr. Michael J. Stamos, dean of the UC Irvine School of Medicine. It symbolizes our commitment to developing advanced treatments for neurological diseases and cancers that position us at the forefront of translational research, clinical trials and patient services, that were once deemed unattainable.

The facility is primarily dedicated to producing cell and gene products that meet stringent GMP regulations enforced by the FDA. In addition, researchers and scientists will use next-generation automated processing and manufacturing technologies, supplemented by leading-edge analytical tools, to produce the transformative therapies essential for clinical trials.

A collaborative effort

The School of Medicine, the Susan & Henry Samueli College of Health Sciences, the Sue & Bill Gross Stem Cell Research Center and the Chao Family Comprehensive Cancer Center and other campus partners have dedicated more than $12 million to the facility.

Our commitment to taking a multidisciplinary approach to integrating groundbreaking research with clinical applications was also recognized and supported by the California Institute for Regenerative Medicine, says Aileen Anderson, Ph.D., director of the UC Irvine Stem Cell Research Center and professor of physical medicine & rehabilitation. We were awarded an initial two-year, $2 million grant to help launch this project, along with membership in the prestigious CIRM Cell and Gene Therapy Manufacturing Network.

Next-generation treatments

The GMP facility has a seven-room cellular therapy and viral vector production area, an adjacent quality control laboratory, and a storage warehouse for raw and finished products. It is designed to create FDA-approved stem cell, engineered chimeric antigen receptor T-cell and gene products for clinical research and treatment across multiple medical disciplines.

These potentially pioneering therapies require meticulous production and processing to meet the complex needs of current clinical trials, enhance delivery and improve patient outcomes. They target a range of conditions, including neurological diseases, spinal cord injuries, autoimmune diseases like multiple sclerosis and lupus, and cancers such as leukemia and lymphoma.

Workforce development

In addition to advancing treatment options, the facility will provide educational opportunities and hands-on experience in GMP processes to prepare the next generation of scientists and clinicians who will lead the development of innovations in regenerative medicine.

By fostering interdisciplinary collaboration, investing in state-of-the-art technology and focusing on comprehensive training, our new facility demonstrates the universitys commitment to translational research and clinical excellence that will offer new treatment options for patients worldwide who will benefit from these groundbreaking discoveries, Stamos says.

If you want to learn more about supporting this or other activities at UC Irvine, please visit the Brilliant Future website. By engaging 75,000 alumni and garnering $2 billion in philanthropic investment, UC Irvine seeks to reach new heights of excellence instudent success,health and wellness, research and more. The School of Medicine plays a vital role in the success of the campaign. Learn more by visiting https://brilliantfuture.uci.edu/uci-school-of-medicine/.

See original here:
Advancing regenerative medicine therapies UCI News - UCI News

Posted in Cell Medicine | Comments Off on Advancing regenerative medicine therapies UCI News – UCI News

To regenerate the kidney, please don’t pass the salt – EurekAlert

Posted: July 2, 2024 at 2:35 am

image:

The kidney contains macula densa cells (green/yellow), which orchestrate kidney regeneration. The circulating plasma is labeled white/gray, and all kidney cells are labeled by their production of genetically inserted green and red fluorescent proteins

Credit: Georgina Gyarmati, MD, PhD Zilkha Neurogenetic Institute

A loss of salt and body fluid can stimulate kidney regeneration and repair in mice, according to a NIH-funded study led by USC Stem Cell scientist Janos Peti-Peterdi and published inThe Journal of Clinical Investigation. This innate regenerative response relies on a small population of kidney cells in a region known as the macula densa (MD), which senses salt and exerts control over filtration, hormone secretion, and other key functions of this vital organ.

Our personal and professional mission is to find a cure for kidney disease, a growing global epidemic affecting one out of seven adults, which translates to 850 million people worldwide or about 2 million in the Los Angeles area, said Peti-Peterdi,a professor of physiology, neuroscience and medicine at theKeck School of Medicine of USC. Currently, there is no cure for this silent disease. By the time kidney disease is diagnosed, the kidneys are irreversibly damaged and ultimately need replacement therapies, such as dialysis or transplantation.

To address this growing epidemic, Peti-Peterdi, first author Georgina Gyarmati, and their colleagues took a highly non-traditional approach. As opposed to studying how diseased kidneys fail to regenerate, the scientists focused on how healthy kidneys originally evolved.

From an evolutionary biology perspective, the primitive kidney structure of the fish turned into more complicated and more efficiently working kidneys to absorb more salt and water, said Peti-Peterdi, who also directs the Multi-Photon Microscopy Core at the Zilkha Neurogenetic Institute (ZNI). This was necessary for adaptation to the dry land environment when the animal species moved from the salt-rich seawater. And thats why birds and mammals have developed MD cells and this beautiful, bigger, and more efficient kidney structure to maintain themselves and functionally adapt to survive. These are the mechanisms that we are targeting and trying to mimic in our research approach.

With this evolutionary history in mind, the research team fed lab mice a very low salt diet, along with a commonly prescribed drug called an ACE inhibitor that furthered lowered salt and fluid levels. The mice followed this regimen for up to two weeks, since extremely low salt diets can trigger serious health problems if continued long term.

In the region of the MD, the scientists observed regenerative activity, which they could block by administering drugs that interfered with signals sent by the MD. This underscored the MDs key role in orchestrating regeneration.

When the scientists furthered analyzed mouse MD cells, they identified both genetic and structural characteristics that were surprisingly similar to nerve cells. This is an interesting finding, because nerve cells play a key role in regulating the regeneration of other organs such as the skin.

In the mouse MD cells, the scientists also identified specific signals from certain genes, including Wnt, NGFR, and CCN1, which could be enhanced by a low-salt diet to regenerate kidney structure and function. In keeping with these findings in mice, the activity of CCN1 was found to be greatly reduced in patients with chronic kidney disease (CKD).

To test the therapeutic potential of these discoveries, the scientists administered CCN1 to mice with a type of CKD known asfocal segmental glomerulosclerosis.They also treated these mice with MD cells grown in low-salt conditions. Both approaches were successful, with the MD cell treatment producing the biggest improvements in kidney structure and function. This might be due to the MD cells secreting not only CCN1, but also additional unknown factors that promote kidney regeneration.

We feel very strongly about the importance of this new way of thinking about kidney repair and regeneration, said Peti-Peterdi. And we are fully convinced that this will hopefully end up soon in a very powerful and new therapeutic approach.

Additional co-authors are Urvi Nikhil Shroff, Anne Riquier-Brison, Dorinne Desposito, Audrey Izuhara, Sachin Deepak, Alejandra Becerra Calderon, James L. Burford, Hiroyuki Kadoya, Ju-Young Moon, Yibu Chen, Nariman Ahmadi, Berislav V. Zlokovic, and Inderbir S. Gill from USC; Wenjun Ju and Matthias Kretzler from the University of Michigan; Sean D. Stocker from the University of Pittsburgh School of Medicine; Markus M. Rinschen from the University of Cologne; Lester Lau from the University of Illinois at Chicago; Daniel Biemesderfer from Yale University School of Medicine; Aaron W. James from Johns Hopkins University; and Liliana Minichiello from the University of Oxford.

This work was federally funded by the National Institutes of Health (grants DK064324, DK123564, DK135290, S10OD021833, and 2P30-DK-081943) and further supported by an American Heart Association predoctoral research fellowship (grant 19PRE34380886).

Disclosure: Peti-Peterdi andGyarmatiare cofounders of Macula Densa Cell LLC, a biotechnology company that develops therapeutics to target MD cells for a regenerative treatment for CKD. Macula Densa Cell LLC has a patent entitled Targeting macula densa cells as a new therapeutic approach for kidney disease (US patents 10,828,374 and 11,318,209). Gill declares equity interest in OneLine Health and Karkinos.

Journal of Clinical Investigation

Experimental study

Animals

Neuronally differentiated macula densa cells regulate tissue remodeling and regeneration in the kidney

10-Apr-2024

Peti-Peterdi and Gyarmati are cofounders of Macula Densa Cell LLC, a biotechnology company that develops therapeutics to target MD cells for a regenerative treatment for CKD. Macula Densa Cell LLC has a patent entitled Targeting macula densa cells as a new therapeutic approach for kidney disease (US patents 10,828,374 and 11,318,209). Gill declares equity interest in OneLine Health and Karkinos.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Link:
To regenerate the kidney, please don't pass the salt - EurekAlert

Posted in Cell Medicine | Comments Off on To regenerate the kidney, please don’t pass the salt – EurekAlert

Cell Therapy Market Size, Share, Growth, Report and Forecast 2024-2032 – openPR

Posted: July 2, 2024 at 2:35 am

Cell Therapy Market Outlook

The cell therapy market was valued at USD 16.30 billion in 2023, driven by the rising burden of chronic diseases and increased funding for cell therapy clinical studies across the globe. The market is expected to grow at a CAGR of 18.1% during the forecast period of 2024-2032, with the values likely to reach USD 72.84 billion by 2032.

Cell Therapy: Introduction

Cell therapy is a cutting-edge biomedical technology that involves the transplantation of human cells to replace or repair damaged tissues and organs, offering promising treatments for a variety of diseases and injuries. Utilizing stem cells, immune cells, and other specialized cells, this innovative approach targets conditions such as cancer, cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases. By harnessing the body's intrinsic healing mechanisms, cell therapy aims to restore normal function, improve patient outcomes, and enhance quality of life. Rapid advancements in research and clinical trials continue to expand its potential, positioning cell therapy at the forefront of personalized medicine and regenerative healthcare.

Get a Free Sample Report with Table of Contents- https://www.expertmarketresearch.com/reports/cell-therapy-market/requestsample

Key Trends in the Global Cell Therapy Market

Key trends in the global cell therapy market include:

Advancements in Manufacturing: Continuous improvements in cell manufacturing processes, including automation and scalability, are enhancing production efficiency and reducing costs.

Regulatory Developments: Evolving regulatory frameworks are shaping the landscape of cell therapy development and commercialization, with efforts to streamline approval processes and ensure patient safety. Increasing Investment: Rising investment from both public and private sectors is fueling research and development activities, driving innovation and expanding the scope of cell therapy applications.

Expansion of Indications: Cell therapies are being explored for a growing range of indications beyond oncology, including cardiovascular diseases, autoimmune disorders, and degenerative conditions. Collaboration and Partnerships: Collaborative efforts between industry players, academic institutions, and government agencies are facilitating knowledge sharing, resource pooling, and the acceleration of clinical development programs.

Personalized Medicine: Advances in cell characterization and patient-specific therapies are enabling the development of personalized treatment approaches tailored to individual genetic profiles and disease characteristics. Commercialization Challenges: Despite promising clinical outcomes, challenges such as reimbursement issues, manufacturing complexities, and market access barriers continue to pose hurdles to the widespread adoption and commercial success of cell therapies. Global Market Expansion: The global cell therapy market is witnessing geographical expansion, with increasing adoption and investment in emerging markets, particularly in Asia-Pacific regions.

Integration of Cell Therapy with Other Modalities: Integration of cell therapy with complementary treatment modalities, such as gene editing and tissue engineering, is unlocking new therapeutic possibilities and synergistic effects. Patient Access and Affordability: Efforts to address concerns related to patient access, affordability, and equitable distribution of cell therapies are gaining prominence, with initiatives aimed at improving healthcare infrastructure and increasing affordability for patients worldwide. Cell Therapy Market Segmentation

Market Breakup by Type

Stem Cell Bone Marrow Derived Mesenchymal Stem Cell Hematopoietic Stem Cells Umbilical Cord Derived Stem Cell Adipose Derived Stem Cell Skin Stem Cells Induced Pluripotent Stem Cells Others Non-Stem Cell (Dendritic Cell, CART-Cell)

Market Breakup by Type of Therapy

Autologous Allogeneic

Market Breakup by Therapeutic Area

Musculoskeletal Disorders Cardiovascular Diseases Neurological Disorders Oncological Disorders Dermatology Inflammatory and Autoimmune Disorders Others

Market Breakup by End User

Hospitals and Clinics Regenerative Medicine Centers Diagnostic and Research Centers Others

Market Breakup by Region

North America Europe Asia Pacific Latin America Middle East and Africa

Read Full Report with Table of Contents- https://www.expertmarketresearch.com/reports/cell-therapy-market

Cell Therapy Market Overview

The global cell therapy market is experiencing significant growth, driven by advancements in biomedical research, increasing prevalence of chronic diseases, and a rising focus on personalized medicine. Cell therapy, which involves the transplantation of human cells to repair or replace damaged tissues and organs, has emerged as a revolutionary approach in treating various conditions, including cancer, cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases.

North America holds a dominant position in the cell therapy market, primarily due to robust healthcare infrastructure, high investment in research and development, and supportive regulatory frameworks. The United States, in particular, is a key player, with numerous biotech companies, research institutions, and clinical trials contributing to the market's expansion. The presence of well-established healthcare facilities and increasing awareness about advanced therapies among patients further bolster the market in this region.

Europe is another significant market for cell therapy, characterized by strong government support and extensive research activities. Countries like Germany, the United Kingdom, and France are leading contributors, driven by a high prevalence of chronic diseases and a growing elderly population. The European Medicines Agency (EMA) provides a conducive regulatory environment, encouraging the development and commercialization of innovative cell-based treatments. Additionally, collaborations between academic institutions and biopharmaceutical companies are propelling market growth in Europe.

The Asia Pacific region is witnessing rapid growth in the cell therapy market, fueled by increasing investments in healthcare infrastructure, rising disposable incomes, and growing awareness about advanced medical treatments. Countries such as Japan, China, and South Korea are at the forefront, with substantial government funding and strategic initiatives to promote regenerative medicine. Japan, in particular, has been a pioneer in cell therapy, with a strong focus on research and clinical applications. The region's large patient pool, coupled with an expanding biotechnology sector, presents significant opportunities for market players.

In Latin America, the cell therapy market is gradually gaining traction, driven by improving healthcare facilities and growing investments in medical research. Brazil and Mexico are key markets in this region, with an increasing number of clinical trials and research programs aimed at exploring the potential of cell-based therapies. Despite facing challenges such as limited funding and regulatory hurdles, the region is poised for growth as awareness about cell therapy continues to rise and technological advancements become more accessible.

The Middle East and Africa region is also emerging as a potential market for cell therapy, albeit at a slower pace compared to other regions. Countries like Israel, the United Arab Emirates, and South Africa are investing in healthcare infrastructure and research initiatives to explore the benefits of regenerative medicine. However, the market's growth in this region is hindered by economic constraints, limited access to advanced medical technologies, and regulatory challenges. Nevertheless, ongoing efforts to improve healthcare services and increasing international collaborations are expected to drive future growth in the cell therapy market.

Cell Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Vericel Corporation

Vericel Corporation is a biopharmaceutical company specializing in advanced cell therapies for the treatment of serious medical conditions. Headquartered in the United States, Vericel focuses on developing innovative therapies derived from a patient's own cells to address unmet needs in areas such as orthopedics and dermatology. Their flagship products include MACI, a cell-based treatment for cartilage defects in the knee, and Epicel, a cultured epidermal autograft for severe burns. With a commitment to scientific excellence and patient care, Vericel continues to advance the field of regenerative medicine through research, development, and commercialization of transformative cell-based therapies.

Kolon TissueGene Inc.

Kolon TissueGene Inc is a biotechnology company specializing in regenerative medicine and cell therapy. Founded in South Korea, it focuses on developing innovative treatments for orthopedic and neurological disorders. The company's flagship product, Invossa, is the world's first cell-mediated gene therapy for osteoarthritis, offering a potentially transformative approach to disease management. Kolon TissueGene Inc is committed to advancing the field of regenerative medicine through cutting-edge research, strategic partnerships, and a dedication to improving patient outcomes. With a focus on addressing unmet medical needs, the company aims to revolutionize the treatment landscape for a range of debilitating conditions.

JCR Pharmaceuticals Co. Ltd

JCR Pharmaceuticals Co. Ltd is a leading biopharmaceutical company based in Japan, specializing in the development, manufacturing, and commercialization of innovative therapeutics and medical devices. With a focus on rare diseases, oncology, and regenerative medicine, JCR Pharmaceuticals is committed to advancing healthcare through cutting-edge research and development efforts. The company leverages its expertise in biologics and recombinant protein technologies to bring novel treatments to patients worldwide. Through strategic partnerships and collaborations, JCR Pharmaceuticals aims to address unmet medical needs and improve the quality of life for patients across a wide range of therapeutic areas.

MEDIPOST Co. Ltd.

MEDIPOST Co. Ltd. is a leading biotechnology company headquartered in South Korea, specializing in the development and commercialization of innovative cell therapies. Founded in 2000, MEDIPOST focuses on utilizing mesenchymal stem cells (MSCs) derived from umbilical cord blood for therapeutic applications. The company's flagship product, CARTISTEM, is an allogeneic MSC-based therapy used for the treatment of osteoarthritis. MEDIPOST is committed to advancing the field of regenerative medicine through cutting-edge research, strategic partnerships, and a dedication to improving patient outcomes. With a strong emphasis on quality, safety, and efficacy, MEDIPOST continues to be at the forefront of cell therapy innovation globally.

Osiris (Mesoblast)

Osiris Therapeutics, now part of Mesoblast, is a pioneering biotechnology company focused on developing innovative cell-based therapies. Specializing in regenerative medicine, Osiris/Mesoblast has made significant strides in leveraging mesenchymal stem cells (MSCs) for treating a variety of medical conditions, including orthopedic disorders, inflammatory diseases, and cardiovascular conditions. Their flagship product, TEMCELL, is approved for graft-versus-host disease (GVHD) in Japan. The company's research pipeline continues to explore the therapeutic potential of MSCs across diverse therapeutic areas, positioning Osiris/Mesoblast as a key player in the field of cell therapy and regenerative medicine.

Other key players in the market include Stemedica Cell Technologies Inc., ImmunoACT, Castle Creek Biosciences, Inc., PHARMICELL Co. Ltd, ANTEROGEN.CO.LTD, Novartis AG, Celgene Corp. (Bristol-Myers Squibb Company), Allogene Therapeutics Inc., and Stempeutics Research Pvt. Ltd.

Related Report

Treatment Resistant Depression Market https://www.expertmarketresearch.com/reports/treatment-resistant-depression-market

Biological Safety Testing Market https://www.expertmarketresearch.com/reports/biological-safety-testing-market

Dry Eye Disease Treatment Market https://www.expertmarketresearch.com/reports/dry-eye-disease-treatment-market

Personal Mobility Devices Market https://www.expertmarketresearch.com/reports/personal-mobility-devices-market

Media Contact:

Company Name: Claight Corporation Contact Person: Joe Goldberg, Business Consultant Email: sales@expertmarketresearch.com Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA

About Us:

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analyses provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organisation's future success by acquiring one of our Expert Market Research reports today.

This release was published on openPR.

View post:
Cell Therapy Market Size, Share, Growth, Report and Forecast 2024-2032 - openPR

Posted in Cell Medicine | Comments Off on Cell Therapy Market Size, Share, Growth, Report and Forecast 2024-2032 – openPR

NeuroStar® Launches Better Me Provider Program Nationwide

Posted: July 2, 2024 at 2:33 am

The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry

Visit link:
NeuroStar® Launches Better Me Provider Program Nationwide

Posted in Global News Feed | Comments Off on NeuroStar® Launches Better Me Provider Program Nationwide

Kraig Biocraft Laboratories Expands Facilities to Support Spider Silk Production Growth

Posted: July 2, 2024 at 2:33 am

ANN ARBOR, Mich., July 01, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has achieved full capacity at its current production location. Hitting this milestone was part of Kraig Labs' expansion plans for the first half of 2024. The Company now reports that it is moving forward with its planned investment into additional production facilities.

Continue reading here:
Kraig Biocraft Laboratories Expands Facilities to Support Spider Silk Production Growth

Posted in Global News Feed | Comments Off on Kraig Biocraft Laboratories Expands Facilities to Support Spider Silk Production Growth

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

Posted: July 2, 2024 at 2:33 am

$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia $8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia

Original post:
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

Posted in Global News Feed | Comments Off on Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

Page 37«..1020..36373839..5060..»